2022-12-122022-12-122016-05-11Atasayar, G. vd. (2016). "Association of MDR1, CYP2D6, and CYP2C19 gene polymorphisms with prophylactic migraine treatment response". Journal of the Neurological Sciences, 366, 149-154.0022-510X1878-5883https://doi.org/10.1016/j.jns.2016.05.019https://www.sciencedirect.com/science/article/pii/S0022510X16302787http://hdl.handle.net/11452/29826Prophylactic therapy response varies in migraine patients. The present study investigated the relationship between the resistance to the drugs commonly used in prophylactic therapy and the possible polymorphic variants of proteins involved in the metabolism of these drugs. Migraine patients with the MDR1 3435TT genotype exhibited a better treatment response to topiramate than migraine patients with the CC and CT genotypes (p = 0.020). The MDR1 C3435T polymorphism was also found to be a higher risk factor for topiramate treatment failure in a comparison of the number of days with migraine (beta(2) = 1.152, p = 0.015). However, there was no significant relationship between the treatment response to topiramate and either the CYP2D6 or CYP2C19 polymorphism, and there were no significant correlations between the treatment responses to amitriptyline, propranolol, and valproic acid and the MDR1, CYP2D6 and CYP2C19 gene polymorphisms. This is the first study to investigate the effect of the polymorphic variants on prophylactic therapy response in migraine patients.eninfo:eu-repo/semantics/closedAccessNeurosciences & neurologyMigraineProphylactic therapy responseMDR1PolymorphismMultidrug-resistanceC3435t polymorphismCytochrome-P450FrequencyAllelesPharmacogeneticsPhenotypeGenotype2C192D6AdultAmitriptylineCentral nervous system agentsCytochrome P-450 CYP2C19Cytochrome P-450 CYP2D6Drug resistanceFemaleFructoseGene frequencyGenetic association studiesHumansMaleMigraine disordersP-glycoproteinsPolymorphism, geneticPropranololRisk factorsTreatment outcomeValproic acidArticle0003791054000302-s2.0-8496994499814915436627288795Clinical neurologyNeurosciencesDrug Resistant Epilepsy; Epilepsy; CarbamazepineAmitriptylineCytochrome P450 2C19Cytochrome P450 2D6Genomic DNAMultidrug resistance protein 1PropranololTopiramateValproic acidABCB1 protein, humanCentral nervous system agentsCYP2C19 protein, humanCytochrome P450 2C19Cytochrome P450 2D6FructoseMultidrug resistance proteinTopiramateAdultAgedArticleDNA polymorphismFemaleGene frequencyGenetic associationGenotypeHumanMajor clinical studyMaleMigraineMigraine with auraMigraine without auraMonotherapyPriority journalProphylaxisTreatment responseAnalogs and derivativesDrug resistanceGenetic association studyGenetic polymorphismGeneticsMigraine disordersRisk factorTreatment outcome